Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Global X MSCI Argentina ETF (ARGT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Global X MSCI Argentina ETF — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $224 (market cap $29.60B), while Global X MSCI Argentina ETF trades at $91.07. The key difference: Global X MSCI Argentina ETF is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | ARGT | |
|---|---|---|
Market Cap | $29.60B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $491.22 | $102.94 |
52-Week Low | $205.48 | $67.55 |
Enterprise Value | $27.56B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $223.43, up 2.97% in 24 hours, with a bearish technical signal despite recent gains. The stock shows strong profitability with a 79.65% gross margin and 96.55% ROE, but valuation ratios like P/E of 38.54 are elevated. Recent Q2 2026 earnings missed estimates, and multiple law firms are investigating potential securities fraud, adding uncertainty.
Outlook is mixed: analyst consensus is bullish with a $370.07 price target, but risks include ongoing fraud probes and earnings volatility. Revenue growth is robust, projected to reach $4.8B in 2026, yet investors face headwinds from legal issues and technical bearishness.
ARGT, the Global X MSCI Argentina ETF, trades at $91.13, down 2.46% on the day, with a bearish technical signal from moving averages. Recent news highlights Argentina's economic reforms under the Milei administration as a potential catalyst. The ETF's valuation is noted as attractive relative to historical averages, though key financial ratios are not currently available in the provided data.
The outlook hinges on Argentina's continued economic stabilization. Upside potential exists if reforms sustain, but significant risks include political volatility and the ETF's heavy concentration in a few holdings like MercadoLibre, which could amplify losses if sentiment sours.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Global X MSCI Argentina ETF
ARGT seeks to provide investment results that correspond to the performance of the MSCI All Argentina 25/50 Index. It offers targeted exposure to some of the largest and most liquid companies operating in Argentina.
Read more on ARGT →
